JP2024501257A5 - - Google Patents
Info
- Publication number
- JP2024501257A5 JP2024501257A5 JP2023538074A JP2023538074A JP2024501257A5 JP 2024501257 A5 JP2024501257 A5 JP 2024501257A5 JP 2023538074 A JP2023538074 A JP 2023538074A JP 2023538074 A JP2023538074 A JP 2023538074A JP 2024501257 A5 JP2024501257 A5 JP 2024501257A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- compound according
- co2h
- groups
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063130023P | 2020-12-23 | 2020-12-23 | |
| US63/130,023 | 2020-12-23 | ||
| PCT/US2021/064881 WO2022140555A1 (en) | 2020-12-23 | 2021-12-22 | Carboxylic acid containing indanyl compounds for the treatment of neurodegenerative diseases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024501257A JP2024501257A (ja) | 2024-01-11 |
| JP2024501257A5 true JP2024501257A5 (https=) | 2024-12-23 |
| JP7851934B2 JP7851934B2 (ja) | 2026-04-27 |
Family
ID=82160119
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023538074A Active JP7851934B2 (ja) | 2020-12-23 | 2021-12-22 | 神経変性疾患の治療のための、インダニルを含むカルボン酸化合物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240124394A1 (https=) |
| EP (1) | EP4267117B1 (https=) |
| JP (1) | JP7851934B2 (https=) |
| KR (1) | KR20230124992A (https=) |
| CN (1) | CN116685313A (https=) |
| WO (1) | WO2022140555A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2022291768A1 (en) | 2021-06-16 | 2023-11-30 | Celgene Corporation | Azetidinyl compounds comprising a carboxylic acid group for the treatment of neurodegenerative diseases |
| JP2024546678A (ja) * | 2021-12-07 | 2024-12-26 | セルジーン コーポレーション | 神経変性疾患治療のためのカルボン酸含有インダニル化合物 |
| WO2024019957A1 (en) * | 2022-07-18 | 2024-01-25 | Celgene Corporation | Compounds for the treatment of neurodegenerative diseases |
| EP4633736A1 (en) * | 2022-12-16 | 2025-10-22 | Celgene Corporation | Heterocyclic compounds as modulators of s1p5 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60335827D1 (de) * | 2002-12-20 | 2011-03-03 | Merck Sharp & Dohme | 1-(amino)indane als edg-rezeptoragonisten |
| US7632854B2 (en) * | 2004-11-17 | 2009-12-15 | Pfizer Italia S.R.L. | Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| US8217027B2 (en) * | 2006-12-21 | 2012-07-10 | Abbott Laboratories | Sphingosine-1-phosphate receptor agonist and antagonist compounds |
| US8637528B2 (en) * | 2007-03-27 | 2014-01-28 | Omeros Corporation | Use of PDE7 inhibitors for the treatment of movement disorders |
| US8592426B2 (en) * | 2011-01-24 | 2013-11-26 | Hoffmann—La Roche Inc. | Aryl-benzocycloalkyl amide derivatives |
| SG10202001065SA (en) * | 2014-03-28 | 2020-04-29 | Azevan Pharmaceuticals Inc | Compositions and methods for treating neurodegenerative diseases |
| EP3228615B1 (en) * | 2014-12-04 | 2021-01-20 | ONO Pharmaceutical Co., Ltd. | Dihydronaphthalene derivatives useful in the treatment of s1p5-mediated diseases |
| TW201730148A (zh) * | 2015-12-22 | 2017-09-01 | 艾伯維德國有限兩合公司 | 作為s1p調節劑的稠合(雜)環化合物 |
-
2021
- 2021-12-22 KR KR1020237024762A patent/KR20230124992A/ko active Pending
- 2021-12-22 WO PCT/US2021/064881 patent/WO2022140555A1/en not_active Ceased
- 2021-12-22 JP JP2023538074A patent/JP7851934B2/ja active Active
- 2021-12-22 CN CN202180087384.3A patent/CN116685313A/zh active Pending
- 2021-12-22 US US18/267,551 patent/US20240124394A1/en active Pending
- 2021-12-22 EP EP21912148.0A patent/EP4267117B1/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024501257A5 (https=) | ||
| JP2024050527A5 (https=) | ||
| JP2023540344A5 (https=) | ||
| JP2021534124A5 (https=) | ||
| JP2011509309A5 (https=) | ||
| JP2021514001A5 (https=) | ||
| JP2020515610A5 (https=) | ||
| JP2022185107A5 (https=) | ||
| JP2022534426A5 (https=) | ||
| JP2022512482A5 (https=) | ||
| JP2024514837A5 (https=) | ||
| JP2021516232A5 (https=) | ||
| JP2010529051A5 (https=) | ||
| JP2012503018A5 (https=) | ||
| JP2024522718A5 (https=) | ||
| JP2010532768A5 (https=) | ||
| JP2013542267A5 (https=) | ||
| JP2011530545A5 (https=) | ||
| JP2020533352A5 (https=) | ||
| JP2019513745A5 (https=) | ||
| FI3681857T3 (fi) | Fluorifenyyli-beeta-hydroksietyyliamiineja ja niiden käyttö hyperglykaemian hoidossa | |
| AR121299A1 (es) | Inhibidores heterocíclicos de pad4 | |
| JP2005539045A5 (https=) | ||
| JP2020111571A5 (https=) | ||
| RU2008107733A (ru) | Ингибиторы gsk-3 |